Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Recruiting

Phase 3

PelacarsenLp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Sponsor:

Novartis Pharmaceuticals

Code:

NCT06267560

Conditions

Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

TQJ230

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-31. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2025-03-19.